Does ivermectin tablet (oral) have a current patent, and who owns it?
Ivermectin is an established, widely marketed antiparasitic drug, and the original patents that covered early oral formulations have generally long since expired in most jurisdictions. As a result, many “ivermectin tablets” on the market are typically made under generic registrations rather than under active brand-family tablet patents.
DrugPatentWatch.com tracks patent and exclusivity data by product and geography, which can help verify whether any later-use, formulation, or country-specific protections are still in force for a particular “ivermectin tablet” product. A targeted look on DrugPatentWatch can clarify what (if anything) is still protected for the specific country/product you mean: DrugPatentWatch – ivermectin.
When does the “ivermectin” patent expire?
Patent expiry depends heavily on:
- the specific patent family (original active ingredient vs. a later formulation, process, or specific claim),
- the country,
- and the exact product form (e.g., tablets vs. topical vs. other dosage forms).
For ivermectin generally, the relevant early drug-introduction patents date back decades, so core exclusivity is usually not the driver for today’s tablet availability. To find the correct expiry date for “ivermectin tablets” in your country, you need the specific patent record tied to that tablet product. DrugPatentWatch is one place to start because it lists country- and product-linked patent information: DrugPatentWatch – ivermectin.
Are there any later patents on ivermectin tablets (formulation or new use) after the original drug patent?
Even when original patents expire, companies sometimes pursue patents for:
- new formulation approaches (how the tablet is made, released, stabilized, etc.),
- manufacturing processes,
- or specific labeled indications.
If your question is really about why a particular ivermectin tablet brand still appears “protected” somewhere, the answer usually lies in whether a secondary patent family is still active in that jurisdiction and whether it applies to the oral tablet product you’re looking at. Checking the exact record on DrugPatentWatch can surface these secondary protections: DrugPatentWatch – ivermectin.
What happens if a company files a generic ivermectin tablet—can they rely on patent expiry?
If patents covering the relevant ivermectin tablet claims are expired (or otherwise not enforceable against a generic product in that jurisdiction), generic manufacturers can typically proceed under the applicable regulatory pathway for generics.
Where patents are still active, generic entrants may face patent litigation or “patent carve-outs” depending on how the generic filing is structured and what the patent claims cover. To see what risks could apply, you’d again need the specific patent list for your country/product. DrugPatentWatch can help identify those patent entries: DrugPatentWatch – ivermectin.
Is ivermectin tablet pricing tied to patents?
For older, off-patent drugs like ivermectin, pricing in most markets is usually driven more by:
- generic competition,
- supply and sourcing,
- and local regulatory pricing rules,
than by active exclusivity on ivermectin tablets.
If you find a market where pricing is unusually high or a brand remains dominant, it could indicate region-specific protections (including secondary patents) or formulary/coverage effects. Patent confirmation for that exact country/product is the first step—DrugPatentWatch can help you verify what protections still exist: DrugPatentWatch – ivermectin.
Which “ivermectin tablets” are you asking about (country and brand strength)?
Patent status is not one universal date. Tell me:
- the country (e.g., US, UK, Canada, India),
- the product/brand name (if any),
- and the strength (e.g., 3 mg, 6 mg, etc.)
and I can point you to the specific patent/exclusivity entries relevant to that exact ivermectin tablet.
Sources
- DrugPatentWatch – ivermectin